Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Zillow Group Inc Class C (Z) Price & Performance

Abbott Laboratories
Zillow Group Inc Class C

Price performance

Price movement over the last 24 hours

Key statistics

Abbott Laboratories vs Zillow Group Inc Class C — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Zillow Group Inc Class C trades at $32.04 (market cap $7.50B). The key difference: Abbott Laboratories is far larger — about 22.3× Zillow Group Inc Class C's market cap, and Abbott Laboratories pays a 2.63% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.

ABTZ
Market Cap
$166.94B$7.50B
Sector
HealthMedia
52-Week High
$136.62$90.35
52-Week Low
$82.57$29.41
Enterprise Value
$193.69B$7.14B
Dividend Yield
2.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.

The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.

Zillow Group Inc Class C

Zillow Group (Z) trades at $32.96, down 1.41% on the day, amid mixed technical signals and ongoing class action lawsuits. The company shows improving fundamentals with revenue growing to $2.58B in 2025 and net income turning positive at $23M, though valuation remains elevated with a P/E of 131.84. Analyst consensus is a Buy with a $63 price target, but legal overhangs and negative cash flow trends present headwinds.

The outlook is cautiously optimistic given strong revenue growth and analyst support, but investment opportunities are tempered by legal risks and high valuation multiples. Key risks include lawsuit outcomes, competitive pressures, and cash flow sustainability, requiring careful monitoring of upcoming Q2 2026 earnings on August 5 for confirmation of profit trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Zillow Group Inc Class C

Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.

Read more on Z